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THE USE OF TISSUE CULTURE IN
THE SCREENING OF HORMONE
SENSITIVITY OF ENDOMETRIAL
CARCINOMA. J. HUSTIN. University of
Liege, Belgium.
Numerous clinical studies have stressed
the frequent hormone responsiveness ofendo-
metrial carcinoma. Nordqvist (Acta obstet.
gynec., scand., 1964, 43, 296) has demon-
strated in vitro a direct cancerocidal effect of
progesterone.
We have tried to assess the response of
endometrial cancer submitted in vitro to
various steroids. Pregnenolone (25 jug/ml of
medium) markedly enhanced the survival and
the cell capacity of mitosis division. Oestra-
diol 17-fl did not influence survival. On the
contrary, progesterone (60-100 ,uLg/ml) and
various synthetic progestogens induced con-
stant necrosis without preliminary secretory
conversion. This necrosis has not been
encountered in non-gynaecological tumours.
Progesterone must be in cell contact for
several hours to display its necrotizing effect.
We suggest that endometrial cancer cells
most often retain steroid binding receptors.
The particular effect of pregnenolone might
suggest the presence of a steroid metabolizing
system affecting cell growth.
RADIOIMMUNOASSAY OF CASEIN
IN THE SERUM OF NORMAL SUB-
JECTS AND OF PATIENTS WITH
VARIOUS MALIGNANCIES. J. C.
HENDRICK and P. FRANCHIMONT. Institute
of Medicine, University of Liege, Belgium.
Radioimmunoassay of casein was carried
out using the double antibody solid phase
(DASP) method. Incubation was at room
temperature for 24 h. This short incubation
period was necessitated by the rapid degrada-
tion of labelled casein. Thus, 5 days after
labelling, the casein no longer reacted with
antibody but became nonspecifically bound
to proteins and to DASP in the absence of
specific antibody.
The characteristics of the radioimmuno-
assay for casein were very satisfactory, as
indicated by the smallest detectable amount,
the precision and the reproducibility as
measured by the coefficient of variation
within assay.
The immunological reaction was deter-
mined by antigenic groups specific to human
casein, there being no cross-reaction whatever
with bovine casein.
Casein was not usually detectable in the
serum ofmen or normal women who were not
lactating. In contrast, allthe seraoflactating
women contained this natural milk product.
In the patients with breast cancer before
treatment, casein was found in 72%. In
contrast, in benign breast lesions this
phosphoprotein was found only rarely.
PREGNENOLONE METABOLISM IN
PATIENTS WITH CARCINOMA. N.
O'HIGcGINS, P. CARSON and N. DESHPANDE
Hammersmith Hospital and Imperial Cancer
Research Fund. London.
In patients with mammary carcinoma,
low blood and urinary levels of androgens
have been associated with a poor prognosis.
Whether this is due to reduced adrenal
synthesis of androgen or altered utilization
of androgen precursor is unknown.
We have studied 20 patients with
mammary carcinoma and have measured
production and metabolic clearance rates of
pregnenolone, which is a precursor both of
the androgen, dehydroepiandrosterone
(DHA), and of cortisol. The DHA: cortisol
ratio did not vary between those with early
and advanced disease. Of 14 patients with
advanced disease treated by endocrine
methods 10 responded favourably and 4
poorly. The mean DHA: cortisol ratio in the
responders (1.2) was signficantly higher than
in the non-responders (0 5).
Pregnenolone metabolic studies may
therefore provide a useful guide to predicting
hormonal responsiveness in mammary carci-
noma.
SERUM OESTRADIOL 17/ IN NOR-
MAL PREMENOPAUSAL WOMEN
AND IN PATIENTS WITH BENIGN
AND MALIGNANT BREAST DIS-
EASE. L. G. SKINNER, P. C. ENGLAND,
K. M. COTTRELL and R. A. SELWOOD.
Clinical Research Laboratories, Christie Hos-
pital and Department of Surgery, University
Hospital of South Manchester.
Evidence exists of a relationship between
ovarian function and development of breast
disease. This study compares levels in
premenopausal women with benign and
malignant disease with the pattern of serum
oestradiol 17/ in normal women.